On October 1, 2024 Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, reported the presentation of two abstracts at the EANM 2024 Congress (Press release, Clarity Pharmaceuticals, OCT 1, 2024, View Source [SID1234646923]). The data showcases Clarity’s optimised bisPSMA product for imaging and treatment of prostate cancer patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, "We are very excited about the trajectory of development for our optimised prostate-specific membrane antigen (PSMA) targeting agent, SAR-bisPSMA, for both imaging and therapy. The EANM Congress is one of the most prestigious conferences in nuclear medicine, and it is fantastic to receive this recognition from our industry. SAR-bisPSMA, built at the benchtop of Australian science, was constructed after thoroughly understanding the limitations of first-generation PSMA targeting molecules, and with the use of some novel chemistry, we were able to overcome these limitations by increasing the uptake and retention of this molecule in prostate cancer. The abstracts accepted for presentation highlight the exciting possibilities of our SAR-bisPSMA product, uniquely positioned for this molecule to become best in class for both the treatment and diagnosis/staging of cancer.

"We are excited to share this remarkable data as we continue to adhere to the highest standards of clinical research, work with world-class clinical sites and generate promising results, while continuously expanding the platform into new indications, targeting high unmet need in the oncology field, so that we can positively impact outcomes for patients in need of innovative treatment options.

"The COBRA results showed that 64Cu-SAR-bisPSMA was able to detect prostate cancer lesions in patients in biochemical recurrence (BCR) of prostate cancer, who had a negative or equivocal standard of care scan at study entry. The study was selected as a Top-Rated Oral Presentation, which underscores the strength of the data and the potentially transformative clinical impact of 64Cu-SAR-bisPSMA in the BCR setting. Regarding our theranostic platform, the case report highlights the potential of 67Cu-SAR-bisPSMA to treat patients with mCRPC. It describes the case of a heavily pre-treated patient who achieved a complete response (anatomical, molecular and biochemical) following 2 cycles of 67Cu-SAR-bisPSMA (8 GBq per cycle). We look forward to further developing our existing and novel Targeted Copper Theranostic (TCT) products and continuing to provide better treatment options for children and adults with cancer."

Product Abstract Title Conference
64Cu-SAR-bisPSMA COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive prostate cancer therapy Presentation Number: OP-428
Session Number: 1006

Session Title: Clinical Oncology Track – Top-Rated Oral Presentation. Session: Oncology & Theranostics Committee – Prostate: Biochemical Recurrence and Re-staging

Session Date: Monday, October 21, 2024

Session Time: 3:00:00 PM – 4:30:00 PM (presentation at 3:50:00 PM – 4:00:00 PM)

Session Hall: Hall Z

67Cu-SAR-bisPSMA Treatment of metastatic castrate-resistant prostate cancer patient with two cycles of 67Cu-SAR-bisPSMA (8 GBq) leads to complete response (RECIST) and undetectable PSA level: A case report Presentation Number: OP-509
Session Number: 1111

Session Title: Case Report Session 1 – Building Our Collective Knowledge on Theranostics

Session Date: Monday, October 21, 2024

Session Time: 4:45:00 PM – 6:15:00 PM

Session Hall: Hall Y1-Y3

More information on the abstracts can be found in the EANM’24 Abstract Book: View Source

Presentations will be available on Clarity’s official website after the EANM 2024 Congress: claritypharmaceuticals.com/pipeline/scientific_presentations